You are here

Our science / Clinical Trials / Find a Trial / NCT01128439

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Back to Search Print Save as PDF Bookmark Trial

NCT01128439

Last updated on December 6, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Kaiser Permanente Vaccine Study Center
Oakland, California, 94612 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Invasive Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S
pneumoniae from a normally sterile site in a member of the surveillance population.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT01128439
Pfizer
Completed
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Similar Trials

Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
NCT03801928
All Genders
18+
Years
Columbia, Maryland
Meningococcal B Disease
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
NCT02534935
All Genders
1+
Years
Multiple Sites
Parkinson Disease
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
NCT02687542
All Genders
40+
Years
Multiple Sites
Intra-Abdominal Infections, Infectious Skin Disease
Tygacil Drug Use Investigation
NCT01789905
All Genders
Study Estimating the Impact of Prevnar 13? (13vPnC) on Invasive Pneumococcal Disease
A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use
This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.
No sampling as no subjects are enrolled
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Primary Care Clinic
Invasive Pneumococcal Disease
Other: No intervention
No intervention
1
Intervention: Other: No intervention
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1
April 2015
April 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S pneumoniae from a normally sterile site in a member of the surveillance population.

Exclusion Criteria:
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01128439
6096A1-4005
B1851042 ( Other Identifier: Alias Study Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Kaiser Permanente
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2015

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now